Articles On Medadvisor (ASX:MDR)

Highlights: The S&P/ASX200 opened a little higher today (July 25). ASX 200 has been taking cues from the Wall Street which closed on a mixed note on Friday. Ten out of eleven sectors on the ASX opened up strong today. The S&am...

Highlights: The S&P/ASX200 opened a little higher today (July 25). ASX 200 has been taking cues from the Wall Street which closed on a mixed note on Friday. Ten out of eleven sectors on the ASX opened up strong today. The S&am...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

MedAdvisor (MDR) appoints US-based CEO and Managing Director, Rick Ratliff In April, current CEO and MD Robert Read announced his intention to retire from the role as he wasn’t prepared to move to the US, in line with the company’s growth...

Antisense announces positive study of ATL1102 Acrux to launch a new product in the US MedAdvisor gets new CEO  Antisense Therapeutics (ASX:ANP) announced a successful study into a new muscle disease indication for its lead drug, ATL1102....

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

MedAdvisor’s (MDR) CEO and Managing Director, Robert Read, intends to retire from his role as the company shifts its focus towards growth in the US Mr Read says he’s unable to commit to relocating to the US due to family reasons and he and...

Rhythm Biosciences releases positive results of ColoSTAT MedAdvisor’s acquisition Adheris exceeds revenue target In a major development today, Rhythm Biosciences (ASX:RHY) was up 15% after announcing that its blood test product ColoSTAT e...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ASX 200 Health Index (XHJ) is trading higher by 0.27% at the time of writing, compared to the broader index which is trading flat. More half year earnings results were announced this morning. Here’s a recap and highlight on where things...

Medtech company MedAdvisor (MDR) enters the New Zealand market via a three-year agreement with Green Cross Health Green Cross Health is a provider of primary health care services in New Zealand and represents 350 community pharmacies under...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

The ASX 200 Health Index (XHJ) is down by 0.70% at the time of writing, compared to the broader index which is down by 0.55%. Health tech MedAdvisor (ASX:MDR) held its AGM this morning, in which it outlined the company’s strategic prioritie...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Today’s top stock was Playside Studios (ASX:PLY), the only ASX listed e-sports developer that’s based in Australia.   Playside Studios (ASX:PLY) Playside is also the newest listed ASX company in this space, debuting last December at 20 cent...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Summary The ASX 200 dropped by 10.50 points or 0.14% to 7,406.90 by lunch. Barring materials, all sectors were trading in red, while utilities and tech declined the most. Origin Energy was the top laggard on ASX, falling nearly 9%. N...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

The MedAdvisor Ltd (ASX: MDR) share price is on the rise today after the company announced a US business update. The medication management platform provider’s shares are currently up 12% to 32.5 cents. Why did the MedAdvisor share price...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

It’s Thursday and who knew buying an Xbox was a bargain? Here’s the news from around the world.   Trump’s Facebook comeback? While Facebook’s independent oversight board may have decided to back the company’s January suspension of former Pr...

The ASX 200 managed to hold on to its lunchtime gains today, finishing the day higher by 0.43 per cent. Health care and Information Tech were the best and worst performing sectors respectively. Geospatial tech company Nearmap (ASX:NEA) rose...

On a day the ASX finished nearly 0.5 per cent up, tech stood alone in the red losing more than 2 per cent. The ASX 200 closed 0.56 per cent up at 7,068 points and the ASX Emerging Companies Index rose 0.41 per cent closing at 2,111 points....

Stockhead taps an extensive list of experts in Money Talks, our regular drill down into the stocks investors are looking at right now. Today, we hear from Justin Rosenberg, executive director of corporate finance at Gleneagle Securities.  ...

The MedAdvisor Ltd (ASX: MDR) share price is soaring today after the company announced an extension of a health program deal. In early afternoon trade, the medication management platform provider’s shares are swapping hands for 33.5 cents,...

In early afternoon trade the S&P/ASX 200 Index (ASX: XJO) is on form and pushing higher again. At the time of writing, the benchmark index is up 0.3% to 6,799.7 points. Four ASX shares that are climbing more than most today are listed...

Global stock markets dipped Stock markets dipped globally on fears over a potential third lockdown in Europe. Wall Street has seesawed throughout the week, as European shares hit a two-week low. Dow Jones was down 0.01%, S&P 500 fell by...

Here’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks for small-cap health companies, with 58 companies gaining ground and 54 losing it. Another 16 were flat. Code Company Price % return...

G’day gang, it’s Thursday already. Here’s your local and global tech news. Don’t forget to tune in for the Startup Daily show on Ausbiz.com.au  every weekday, 2-2.45pm. Watch online, download the ausbiz app or via 7Plus. Square buys BTC Ja...

Summary MedAdvisor has experienced significant growth in the US after an acquisition, which was completed in November.  It is also entering new markets to drive the expansion of its platform.  MedAdvisor (ASX:MDR) shares closed nea...

Summary In 2020, the stock market stayed highly volatile due to the negative impact of the coronavirus pandemic.  However, the healthcare sector remained relatively stable and managed to give good returns to the investors. CogState, P...

Future prospects of the health booking platform – 1st Group – with some new opportunities on the horizon By Tim Boreham How a founder’s ASX-listed healthcare platform saved his own life Health platform founder Klaus Bartosch offers an unusu...

The MedAdvisor Ltd (ASX: MDR) share price has been a positive performer on Monday morning. At the time of writing, the medication management platform provider’s shares are up 2.5% to 40 cents. Why is the MedAdvisor share price pushing high...

The MedAdvisor Ltd (ASX: MDR) share price is up 8.22% to 40 cents after the medtech company released second-half results for its newly acquired Adheris subsidiary. The results show that Adheris is performing stronger than expected.  Wha...

Earlier this week I looked at a couple of healthcare shares that have been tipped as potential market-beaters. Today, I thought I would take a look at the healthcare sector again, but this time at the small end of town. Two small cap healt...

In afternoon trade the S&P/ASX 200 Index (ASX: XJO) has followed the lead of U.S. markets and is pushing higher. At the time of writing, the benchmark index is up 0.2% to 6,498.3 points. Four shares that have failed to follow the marke...

The MedAdvisor Ltd (ASX: MDR) share price was a strong performer on Friday. The medication management platform provider’s shares were up as much as 9% to 42.5 cents at one stage. The MedAdvisor share price ultimately ended the day 6.5% hig...

Medical software group MedAdvisor (ASX: MDR) has come to the diagnosis that a discount may work better for its recently launched capital raise to acquire US-based Adheris Health. Earlier this week the Melbourne-based group launched a $45...

The MedAdvisor Ltd (ASX: MDR) share price will be one to watch later this week when it returns from its trading halt. Why is Medadvistor in a trading halt? This afternoon the medication management platform provider requested a trading halt...

Medical software group MedAdvisor (ASX: MDR) is prepared to massively dilute current shareholdings to secure the funds for a $49 million acquisition of Adheris LLC. The Melbourne-based company has entered into a binding agreement to acqui...